What is Vicore Pharma Holding AB (publ)'s (VICO.ST) StockRank?

MoatMap's StockRank for Vicore Pharma Holding AB (publ) (VICO.ST) is 15/100, with a Strong Sell signal. This is a composite score combining Quality (25), Value (25), and Momentum (52) factor ranks across MoatMap's 19,000+ stock universe.

Does Vicore Pharma Holding AB (publ) have an economic moat?

Vicore Pharma Holding AB (publ) (VICO.ST) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Vicore Pharma Holding AB (publ) a buy, hold, or sell?

MoatMap's current signal for Vicore Pharma Holding AB (publ) (VICO.ST) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Vicore Pharma Holding AB (publ) in?

Vicore Pharma Holding AB (publ) (VICO.ST) operates in the Healthcare sector, specifically the Biotechnology industry (Sweden).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VICO.ST

STRONG SELLREMOVE

Vicore Pharma Holding AB (publ) · Healthcare · Sweden · $356M · Avg Vol: $793K/d

StockRank

P/E (TTM)

—

ROE

-47.2%

D/E

—

Dividend %

—

Director Trades · 180d

+$183.7K →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Vicore Pharma is a clinical-stage biotech company with high binary trial risk and no current revenues, failing our quality and predictability standards.

COMPANY DESCRIPTION

Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company focused on developing novel small molecule drugs for rare lung and other interstitial lung diseases. Vicore Pharma's competitive moat is its innovative drug pipeline targeting underserved rare diseases, particularly its lead candidate C21 with a novel mechanism of action. It is a specialized biotechnology company focused on developing first-in-class treatments for rare lung diseases.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	12M	414,340	-96.5%
EPS	-0.42	-0.35	-0.13	-0.22	—
Shares	84M	115M	235M	282M	+234.7%
Debt	5M	5M	7M	13M	36.0%
Equity	31M	49M	123M	119M	55.9%
Op CF	-33M	-27M	-18M	-41M	—
Inv CF	8M	-16M	16M	-65M	—
Fin CF	20M	51M	91M	47M	—

PRICE (1M)+4.9%

SMA 50SMA 200

$1.16

RSI (14)

37.4

52W High

$1.53

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-43.4%16.5

ROE

-47.2%18.9

GP/Assets

1.1%12.6

Op. Margin

-17921.4%1.4

FCF/Assets

-19.6%17.3

Piotroski

—28.8

Int. Cover

-50.0x6.5

D/E Ratio

—N/A

Current Ratio

12.69x90.7

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

3.0x39.6

P/S

847.7x2.9

Div Yield

—N/A

Momentum

52W High %

76%67.4

RS 6M

-8%70.9

SMA 50/200

0.98x58.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-1%20.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$356M

P/E (Forward)

-5.5x

Gross Margin

370.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VICO.ST are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
VICO.ST	Vicore Pharma Holding AB (publ)(you)	$356M	15	STRONG SELL
EGTX.ST	Egetis Therapeutics AB (publ)	$297M	22	SELL
BINV.ST	BioInvent International AB (publ)	$239M	20	STRONG SELL
HNSA.ST	Hansa Biopharma AB (publ)	$365M	30	SELL
FLERIE.ST	Flerie AB (publ)	$242M	23	SELL
XSPRAY.ST	Xspray Pharma AB (publ)	$126M	5	STRONG SELL
IBT-B.ST	Infant Bacterial Therapeutics AB (publ)	$82M	18	STRONG SELL
SYNACT.ST	SynAct Pharma AB	$102M	7	STRONG SELL
MVIR.ST	Medivir AB (publ)	$118M	27	SELL
ONCO.ST	Oncopeptides AB (publ)	$76M	6	STRONG SELL

Peer medians: ROE 5.1% · P/E 37.9x · Gross margin 59.4%

Vicore Pharma Holding AB (publ) (VICO.ST) — Stock Score Summary

Vicore Pharma Holding AB (publ) (VICO.ST) has a MoatMap StockRank of 15/100 based on Quality (25/100), Value (25/100), and Momentum (52/100) factor scores. The current signal is STRONG SELL. Vicore Pharma is a clinical-stage biotech company with high binary trial risk and no current revenues, failing our quality and predictability standards.

Key Financial Metrics

Price	$1.16
Market Cap	$356M
P/E (Forward)	-5.53
Price/Book	2.98
Return on Equity	-47.2%
Return on Invested Capital	-43.4%
Gross Margin	370.6%
Operating Margin	-17921.4%
Revenue Growth	-32.5%
Free Cash Flow	$-3M

Vicore Pharma Holding AB (publ) operates in the Biotechnology industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Vicore Pharma Holding AB (publ)’s (VICO.ST) StockRank?: MoatMap’s StockRank for Vicore Pharma Holding AB (publ) (VICO.ST) is 15/100, with a Strong Sell signal. It is a composite of Quality (25), Value (25), and Momentum (52) factor ranks across MoatMap’s 19,000+ stock universe.
Does Vicore Pharma Holding AB (publ) have an economic moat?: Vicore Pharma Holding AB (publ) (VICO.ST) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vicore Pharma Holding AB (publ) a buy, hold, or sell?: MoatMap’s current signal for Vicore Pharma Holding AB (publ) (VICO.ST) is Strong Sell, based on a StockRank of 15/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Vicore Pharma Holding AB (publ) in?: Vicore Pharma Holding AB (publ) (VICO.ST) operates in the Healthcare sector, specifically the Biotechnology industry (Sweden).